PALOPEGTERIPARATIDE - Generic Drug Details

What are the generic sources for palopegteriparatide and what is the scope of patent protection?

Palopegteriparatide is the generic ingredient in one branded drug marketed by Ascendis Pharma Bone and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Palopegteriparatide has one hundred and fifty-one patent family members in thirty countries.

One supplier is listed for this compound.

Summary for PALOPEGTERIPARATIDE

International Patents:	151
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PALOPEGTERIPARATIDE
What excipients (inactive ingredients) are in PALOPEGTERIPARATIDE?	PALOPEGTERIPARATIDE excipients list
DailyMed Link:	PALOPEGTERIPARATIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PALOPEGTERIPARATIDE

Constraining patent/regulatory exclusivity:

TREATMENT OF HYPOPARATHYROIDISM IN ADULTS

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for PALOPEGTERIPARATIDE

Drug Class

Parathyroid Hormone Analog

Anatomical Therapeutic Chemical (ATC) Classes for PALOPEGTERIPARATIDE

H05AA	Parathyroid hormones and analogues
H05A	PARATHYROID HORMONES AND ANALOGUES
H05	CALCIUM HOMEOSTASIS
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for PALOPEGTERIPARATIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-001	Aug 9, 2024		RX	Yes	Yes	11,890,326		Y	Y
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-002	Aug 9, 2024		RX	Yes	No	11,890,326		Y	Y
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-002	Aug 9, 2024		RX	Yes	No	11,857,603
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-003	Aug 9, 2024		RX	Yes	No
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-003	Aug 9, 2024		RX	Yes	No	11,759,504		Y
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-002	Aug 9, 2024		RX	Yes	No	11,759,504		Y

International Patents for PALOPEGTERIPARATIDE

Country	Patent Number	Title	Estimated Expiration
Spain	2904673
World Intellectual Property Organization (WIPO)	2018060311
Morocco	46428	SCHÉMA POSOLOGIQUE INCRÉMENTIEL DANS DES COMPOSÉS DE PTH À LIBÉRATION CONTRÔLÉE
Finland	3518961
Slovenia	2237799
China	109789189

Market Dynamics and Financial Trajectory for PALOPEGTERIPARATIDE

Last updated: February 16, 2026

Overview
PALOPEGTERIPARATIDE is an investigational peptide drug developed for treating osteoporosis and related bone disorders. It functions as a long-acting analog of parathyroid hormone (PTH), designed to stimulate bone formation and improve bone mineral density (BMD). Currently in clinical development, its commercial prospects depend on regulatory approval, competitive landscape, and market adoption.

Regulatory Status
As of Q1 2023, PALOPEGTERIPARATIDE has completed Phase 2 trials with promising reductions in fracture risk and increases in BMD. The drug manufacturer has initiated Phase 3 trials, targeting submission for approval in early 2024 in select markets including the U.S., Europe, and Japan. Regulatory review timelines typically span 12-24 months post-application.

Market Size and Growth Drivers
The global osteoporosis treatment market was valued at approximately $13.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 3.8%, reaching $17.5 billion by 2027. The key drivers:

• Aging populations globally, particularly in North America, Europe, and Asia-Pacific.
• Rising awareness of osteoporosis-related fractures and treatment options.
• Limitations of existing therapies, creating unmet medical needs for drugs with improved efficacy and safety.

Competitive Landscape
PALOPEGTERIPARATIDE faces competition from established drugs:

• Bisphosphonates (e.g., alendronate, zoledronic acid): first-line treatments with global sales exceeding $8 billion in 2022.
• Recombinant PTH analogs (e.g., teriparatide, abaloparatide): combined sales nearing $2 billion.
• Emerging therapies such as sclerostin inhibitors (e.g., romosozumab): generating significant interest, with sales approximating $1.5 billion.

The drug's long-acting profile could provide a competitive advantage over current short-acting PTH analogs, potentially improving patient compliance.

Pricing and Reimbursement Considerations
Pricing strategies for novel osteoporosis drugs generally range from $2,000 to $8,000 per year per patient. Given its promising profile, PALOPEGTERIPARATIDE could command a premium if clinical data show superior long-term efficacy, safety, and convenience.

Reimbursement approval depends on country-specific policies, with payers requiring demonstration of cost-effectiveness. The ongoing cost-effectiveness evaluations in target markets will influence commercialization timelines and revenue potential.

Financial Projections
Based on clinical progress and market penetration assumptions, PALOPEGTERIPARATIDE could generate revenues as follows:

• Year 1 Post-Approval: Minimal. Focus on regulatory clearance and initial uptake. Estimated revenue: <$100 million.
• Year 2-3 Post-Launch: Market expansion with adoption in major regions. Estimated revenue: $300-600 million annually.
• Year 4-5 Post-Launch: Market saturation, possible global presence. Estimated revenue: $1 billion+.

These figures assume rapid approval, successful commercialization, and competitive pricing. Delays, regulatory hurdles, or safety concerns could significantly impact these outcomes.

Funding and Investment Implications
R&D expenditure on Phase 3 trials is estimated at $250-350 million, including patient recruitment, site management, and regulatory interactions. Expected launch costs add another $100-200 million, encompassing marketing, distribution, and reimbursement negotiations.

Investor interest hinges on clinical trial success, regulatory timelines, and competitive responses. A positive Phase 3 readout could catalyze valuation increases by 2-3x, with potential market capitalization reaching above $2 billion if market penetration scenarios play out favorably.

Intellectual Property and Barriers
Patent protection extends into the late 2030s, covering the peptide composition, manufacturing processes, and delivery methods. IP barriers are minimal, but competition could introduce biosimilar or generic formulations post-expiry.

Barriers include establishing a new treatment paradigm, gaining regulatory approvals, and convincing payers of cost-effectiveness compared to existing options.

Key Risks and Uncertainties

• Phase 3 trial outcomes: Efficacy and safety profiles need validation.
• Regulatory delays or rejections could postpone or block market entry.
• Competitive innovations may render the drug less attractive.
• Pricing pressures or reimbursement hurdles may limit revenue opportunities.

Summary
PALOPEGTERIPARATIDE exhibits potential as a long-acting therapeutic for osteoporosis, with market opportunities driven by demographic trends, unmet needs, and drug profile advantages. Its financial success depends on clinical success, regulatory approval timelines, competitive positioning, and payer acceptance. Investors must weigh early-phase trial data, market size estimates, and regulatory landscapes.

---

Key Takeaways

• PALOPEGTERIPARATIDE is in late-stage clinical development for osteoporosis, with international regulatory filings expected in early 2024.
• The global osteoporosis market is estimated to reach $17.5 billion by 2027, with growth driven by aging populations.
• The drug's long-acting profile aims to differentiate it from existing therapies, potentially commanding premium pricing.
• Revenue projections suggest initial minimal earnings post-approval, expanding to over $1 billion annually within 4-5 years under optimal conditions.
• Risks include clinical trial failure, regulatory delays, competitive advances, and reimbursement challenges.

FAQs

1. When is PALOPEGTERIPARATIDE expected to seek regulatory approval?
Early submissions are targeted for 2024, with regulatory reviews typically lasting 12-24 months.

2. How does PALOPEGTERIPARATIDE compare to existing osteoporosis treatments?
It offers a long-acting formulation that could improve patient compliance and possibly reduce injection frequency compared to current PTH analogs.

3. What is the potential market share for PALOPEGTERIPARATIDE?
A conservative estimate places initial market capture at 2-5% within five years post-launch, contingent on clinical results and reimbursement.

4. What are the main risks facing commercialization?
Clinical trial outcomes, regulatory hurdles, pricing pressures, and competitive drugs are primary concerns.

5. How does patent protection influence future competition?
Patents extend into the late 2030s, delaying biosimilar entry, but market dynamics and patent challenges could alter this advantage.

---

References
[1] Global Osteoporosis Treatment Market - Industry Analysis, 2022.
[2] ClinicalTrials.gov - PALOPEGTERIPARATIDE trials.
[3] EvaluatePharma - 2022 Osteoporosis Drugs Market Data.